Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2019

View Archived Issues

A spoonful of sugar makes antigen work better

Coronavirus is PARP's side hustle

Mouse model devised for hypomyelination and atrophy of basal ganglia and cerebellum

Positive early results seen with E6/E7 RNA(LIP) cancer vaccine in first clinical study

New phase II trial studies HLX-10 for advanced MSI-H and dMMR solid tumors

First results from HD-CAR-1 trial on anti-CD19 CAR T cells for CD19+ lymphoid neoplasias

The Medicines Company reports long-term data on effects of inclisiran sodium on LDL-C

NX-13: a novel NLRX1-targeting immunometabolic therapeutic for UC

COX and LOX: For immune response, tolerance beats scorched-earth

First-in-human data with BIO89-100 support further development for NASH

SAkuraSky study shows satralizumab reduces relapse of neuromyelitis optica in AQP4-IgG+ patients

Kangpu initiates first-in-human study of KPG-818 for SLE

Bayer patents alpha2B-adrenoceptor antagonists

Heptares Therapeutics discloses new orexin OX1 receptor antagonists

GlaxoSmithKline presents new compounds for HIV infections

Novartis describes muscarinic M1-M5 receptor ligands

CC-220 generally well tolerated in pilot study in systemic lupus erythematosus

New compounds for obesity presented by Ube Industries

Entyvio approved in Japan for moderate to severely active Crohn's disease

DT-0111, a P2X2/3 receptor antagonist for COPD and chronic cough

Beta Bionics and Zealand initiate home-use trial of the iLet bionic pancreas with dasiglucagon

Autoantibodies against LL37 and ADAMTSL5 are elevated in psoriasis and psoriatic arthritis

Interim data from phase II study of Tavo with Keytruda in heavily pretreated metastatic TNBC

New dosage and administration of Genvoya approved in Japan for pediatric HIV-1 infection

Phase II study of mirikizumab in moderate to severely active Crohn's disease meets primary endpoint

Altasciences to guide development of RAP-103 peptide as chemical nerve agent therapeutic

Actemra approved in Japan for adult-onset Still's disease

Targovax reports 3-year survival data from phase I/II study of TG-101 in resected pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...